# US 2018/0021381 A1 · Adipose tissue-derived stem cells for veterinary use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021381 A1
- Document ID: US20180021381A1
- Status: Published application
- Kind: A1
- Application number: 15/700,604
- Filed: 2017-09-11
- Published: 2018-01-25
- Earliest claimed: 2008-06-11
- Assignees: Cell4Vet Corporation
- Applicants: Cell4Vet Corporation
- Inventors: Ching Shwun LIN; Tom F. LUE; Guiting LIN
- Web page: https://patentgrep.com/patent/US20180021381A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/10: of the bladder
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- C12N 2500/84: from mammals
- C12N 2531/00: Microcarriers
- C12N 2533/40: Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- C12N 2533/78: Cellulose
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

## Claims

### Claim 1

A method of treating a medical condition in a non-human mammal in need thereof comprising administering to the non-human mammal an effective amount of a purified population of porcine adipose tissue-derived stem cells (ADSC),
wherein the medical condition is one or more condition selected from the group consisting of: degenerative myelopathy, diabetes, tissue regeneration, wound healing, scarring, soft tissue defect, fecal incontinence, dilated cardiomyopathy, hip dysplasia, avascular necrosis of the femoral head, ligament injury, tendon injury, spinal cord injury, atherosclerosis-related infarctions, muscular dystrophy, pain, and inflammation, and
wherein the ADSC are xenogenic to the non-human mammal.

### Claim 2 (depends on 1)

The method of claim 1, wherein the non-human mammal is selected from the group consisting of dog, cat, horse, rabbit, monkey, baboon, chimpanzee, orangutan, tiger, lion, bear, cheetah, and llama.

### Claim 3 (depends on 1)

The method of claim 1 wherein the effective amount of ADSC is within in the range of 0.05×106 to 100×106 ADSC.

### Claim 4 (depends on 3)

The method of claim 3 wherein the effective amount of ADSC is within in the range of 1×106 to 107 ADSC.

### Claim 5 (depends on 1)

The method of claim 1 wherein the effective amount of ADSC is 0.5×106 ADSC/kg of body weight of the non-human mammal.

### Claim 6 (depends on 1)

The method of claim 1, wherein the purity of the purified population is by cell number of the population

### Claim 7 (depends on 6)

The method of claim 6 wherein the purified population is with the range of 60% to 99% pure.

### Claim 8 (depends on 7)

The method of claim 7 wherein the purified population is with the range of 80% to 99% pure.

### Claim 9 (depends on 8)

The method of claim 8 wherein the purified population is with the range of 80% to 99% pure.

### Claim 10 (depends on 9)

The method of claim 9 wherein the purified population is with the range of 90% to 99% pure.

### Claim 11 (depends on 1)

The method of claim 1, wherein the effective amount is delivered by intravenous administration.

### Claim 12 (depends on 1)

The method of claim 1, comprising delivery of a composition comprising the effective amount of the purified population of porcine adipose tissue-derived ADSC and at least one of a pharmaceutically acceptable carrier, excipient, adjuvant, or diluent.

### Claim 13 (depends on 12)

The method of claim 12, wherein the pharmaceutically acceptable carrier, excipient, adjuvant, or diluent is chemically inert to the effective amount of the purified population of porcine adipose tissue-derived ADSC.

### Claim 14

A bank of porcine ADSC for use in treatment of a medical condition wherein the ADSC is xenogeneic to the recipient of the ADSC and wherein the medical condition is one or more condition selected from the group consisting of: degenerative myelopathy, diabetes, tissue regeneration, wound healing, scarring, soft tissue defect, fecal incontinence, dilated cardiomyopathy, hip dysplasia, avascular necrosis of the femoral head, ligament injury, tendon injury, spinal cord injury, atherosclerosis-related infarctions, muscular dystrophy, inflammation and pain.

### Claim 15 (depends on 14)

The bank of porcine ADSC of claim 14 wherein the ADSC comprise carboxymethylcellulose (CMC).

### Claim 16

A composition comprising a purified population of porcine ADSC and CMC for use in xenotransplantation.

### Claim 17 (depends on 16)

The composition of claim 16 wherein the xenotransplantation does not result in any significant rejection of the composition.
